Spencer E K, Campbell M
Dept. of Psychiatry, New York University School of Medicine, NY 10016.
Schizophr Bull. 1994;20(4):713-25. doi: 10.1093/schbul/20.4.713.
This article presents data on the diagnosis and phenomenology of schizophrenia in 16 hospitalized children, ages 5.5 to 11.75 years. These 16 subjects are the first to complete an ongoing double-blind, placebo-controlled study of haloperidol in children with schizophrenia diagnosed by DSM-III-R criteria. We describe the pharmacologic treatment response of this subsample and compare our diagnostic, phenomenologic, and treatment findings with those of other investigators. Our results show that children under age 12 can be diagnosed with schizophrenia by the same criteria used for adults, that they show comparable clinical symptoms, and that on haloperidol they show improvement in target psychotic symptoms, at least in a short-term inpatient setting.
本文呈现了16名住院儿童（年龄在5.5至11.75岁之间）精神分裂症的诊断及症状学数据。这16名受试者是首批完成一项正在进行的、针对符合DSM-III-R标准诊断的儿童精神分裂症患者使用氟哌啶醇进行的双盲、安慰剂对照研究的。我们描述了该子样本的药物治疗反应，并将我们的诊断、症状学及治疗结果与其他研究者的结果进行了比较。我们的结果表明，12岁以下儿童可采用与成人相同的标准诊断精神分裂症，他们表现出相似的临床症状，且使用氟哌啶醇后，至少在短期住院环境中，其目标性精神病性症状有所改善。
